► Vaginal melanoma in situ is a rare neoplasm with a paucity of data regarding the optimal management. ► More conservative approaches are needed to avoid the disfigurement, pain and postoperative complications associated with repeated surgical interventions. ► Imiquimod may prove to be a useful treatment modality for patients with vulvar or vaginal melanoma in situ.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860951 | PMC |
| http://dx.doi.org/10.1016/j.gynor.2012.04.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary malignant melanoma of the vagina: A case report of a rare disease that is difficult to diagnose.
Medicine (Baltimore)
January 2025
Department of Obstetrics and Gynecology, Dong-A University, College of Medicine, Busan, Republic of Korea.
Rationale: Malignant melanoma is a rare cancer that accounts for approximately 1% of all cancers. Primary malignant melanoma of the female genital tract accounts for approximately 3% to 7% of all malignant melanomas, and 0.3% to 0.
View Article and Find Full Text PDFInvestigating the Local Effectiveness of Carbon Ion Radiotherapy for Unresectable Female Genital Tract Melanomas: A Preliminary Real-World Study.
Cancers (Basel)
December 2024
Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, 27100 Pavia, Italy.
: Primary gynecological melanomas are rare malignancies with lower survival rates compared to cutaneous melanomas. Both preclinical and clinical data support the evidence that mucosal melanomas are photon-radioresistant but responsive to carbon ion radiotherapy (CIRT). The aim of this study is to assess, in a real-world cohort, the effectiveness and tolerability of radical CIRT in patients with inoperable gynecological mucosal melanoma.
View Article and Find Full Text PDFClinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study.
Melanoma Res
February 2025
Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
Vulvar and vaginal melanomas (VVMs) are rare malignancies, but they are relatively more common among Asian women. This makes the collection of data on VVMs in this population crucial. Moreover, no cohort studies have examined and compared the effects of immune checkpoint inhibitors (ICIs) on VVM in Asian women.
View Article and Find Full Text PDFSurvival Outcomes in Patients Undergoing Pelvic Exenteration for Pelvic Mucosal Melanomas: Retrospective Single Institution Australian Study.
Dis Colon Rectum
December 2024
Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.
Background: Pelvic mucosal melanomas, including anorectal and urogenital melanomas, are rare and aggressive with a median overall survival of up to 20 months. Pelvic mucosal melanomas behave differently to its cutaneous counterparts and presents late with locoregional disease, making pelvic exenteration its only curative surgical option.
Objective: This study aimed to evaluate the survival outcomes post pelvic exenteration in pelvic mucosal melanomas at Royal Prince Alfred Hospital.
The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma.
Int J Gynecol Cancer
December 2024
Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Article Synopsis
- The study aimed to investigate the relationship between the immune microenvironment and survival outcomes in patients with vulvovaginal melanoma.
- It involved a retrospective analysis of 42 patients, examining tumor-infiltrating lymphocytes and genetic mutations, with significant findings on immune cell presence related to better disease-free survival.
- The researchers concluded that specific types of tumor-infiltrating lymphocytes could indicate disease progression and response to treatments, suggesting the need for further multicenter studies to confirm these results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!